{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-022283","form_type":"8-K","ticker":"CODX","cik":"0001692415","company_name":"Co-Diagnostics, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.162219+00:00","generated_at":"2026-05-16T20:27:30.758120+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Co-Diagnostics Q3 net loss narrows to $5.9M; announces JV in Saudi Arabia and SPAC exploration for India unit","bullets":["Revenue $0.1M, down from $0.6M YoY; net loss $5.9M ($0.16/share) vs $9.7M ($0.32) in Q3 2024.","Operating loss $7.0M vs $10.2M; adjusted EBITDA loss $6.3M.","Cash and marketable securities $11.4M at Sept 30, 2025.","Signed JV with Arabian Eagle Manufacturing for CoMira Diagnostics in KSA and 18 MENA nations.","Engaged Maxim Group to pursue SPAC transaction for CoSara India JV; closed RDOs totaling ~$10.8M gross."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-022283","json":"https://secwatch.observer/filing/0001493152-25-022283.json","markdown":"https://secwatch.observer/filing/0001493152-25-022283.md","text":"https://secwatch.observer/filing/0001493152-25-022283.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1692415/000149315225022283/0001493152-25-022283-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1692415/000149315225022283/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:27:30.758120+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}